Who owns Cogent Biosciences, Inc. (COGT)? Elite investor 13F holders
3 tracked elite investors reported holding Cogent Biosciences, Inc as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC, Oaktree Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | Cogent Biosciences Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 35699937.00 USD | 922479.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | Cogent Biosciences Inc | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 38551702.00 USD | 996168.000000 | Shares | add | Original filing |
| Oaktree Capital Management | COGENT BIOSCIENCES INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 14758452.00 USD | 11890000.000000 | Principal | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.